Litcius/Paper detail

Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study

Neil D. Gross, David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, Yungpo Bernard Su, Paul Swiecicki, Jennifer Atlas, J.L. Geiger, Axel Hauschild, Jennifer H. Choe, Brett Hughes, Dirk Schadendorf, Vishal Patel, Jade Homsi, Janis M. Taube, Annette M. Lim, Renata Ferrarotto, Suk‐Young Yoo, Melissa Mathias, Hyunsil Han, Frank Seebach, Israel Lowy, Matthew G. Fury, Danny Rischin

2023The Lancet Oncology99 citationsDOI

Topics & Concepts

MedicineClinical endpointInternal medicineStage (stratigraphy)Neoadjuvant therapyOncologyRadiation therapyCarcinomaPathologicalClinical trialCancerBreast cancerPaleontologyBiologyNonmelanoma Skin Cancer StudiesCutaneous Melanoma Detection and ManagementCancer and Skin Lesions
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study | Litcius